Markers of autoimmune diseases
AssigneesSorbonne Universite, Institut National De La Sante Et De La Recherche Medicale (Inserm), Assistance Publique-Hopitaux de Paris
InventorsCindy MARQUES, Paul REGNIER, David SAADOUN
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of diagnosis and treatment of autoimmune, chronic inflammatory and lymphoproliferative diseases based on the identification of a population of pathogenic B and/or T cells showing a specific phenotype. These cells may be identified by their specific pattern of expression of marker proteins.
Claims10
A method of diagnosing of pSS, L-pSS and lymphoma in a subject, comprising obtaining a test sample from the subject and detecting the presence of pathogenic B cells in the test sample, that express the marker proteins CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and/or G6 at a different level compared to a baseline level established from a healthy donor sample and wherein the presence of said pathogenic B cells in the sample, identifies the subject as having or likely to develop the autoimmune disease or a lymphoproliferative form or a chronic inflammatory form of an autoimmune disease.
A method for an in vitro detection of pathogenic B cells, the method comprising:
- detecting CD19, CD27, CD21, CD11c, and CXCR5, and optionally at least one marker protein selected from the group consisting of:
- Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and G6, as markers for the in vitro detection of pathogenic B cells.
A method of detection of pathogenic B cells in a subject, comprising obtaining a biological sample from the subject and determining the level of cellular expression of CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95 and/or FCRL3, wherein expression CD19+CD27− CD21− CD11c++ CXCR5+ Tbet++CD95+ FCRL3+ for the markers for which the level cellular expression has been determined is indicative of pathogenic B cells.
An in vitro detection method of pathogenic B cells in a biological sample from a patient comprising the steps of:
- (i) determining the level of cellular expression of CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95 and/or FCRL3 of B cells in the biological sample;
- (ii) in vitro detection of the expression CD19+CD27− CD21− CD11c++ CXCR5+ Tbet++CD95+ FCRL3+ in B cells from the biological sample, for the markers for which the level cellular expression has been determined, the detection of this expression denoting the presence of pathogenic B cells in the biological sample.
A kit for the diagnosis of pSS, L-pSS and lymphoma in a subject or for the detection of pathogenic B cells, comprising reagents, each being used to determine the expression level of one of the marker proteins CD19, CD27, CD21, CD11c, CXCR5, and optionally Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and/or G6 in a sample.
A method to evaluate the efficacy of a treatment of an autoimmune disease or a lymphoproliferative form or a chronic inflammatory form of an autoimmune disease in a subject, comprising determining the expression of marker proteins CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and/or G6 in B cells in a sample taken from the subject before administering the treatment;
- detecting the presence of pathogenic B cells in a sample taken from the subject after administering the treatment;
- and comparing the level of expression of said marker proteins in the sample taken from the subject before administering the treatment to the level expression of said marker proteins in the sample taken from the subject after administering the treatment.
8-16. (canceled)
Dependencies are inferred from the claim text.